News Industry News NaviGate Cardiac Structures, Inc. (“NCSI”) reports first heterotopic transcatheter GATE™ tricuspid valved stent successful implantation April 26, 2017
News Daily News Rapid Rule-Out Strategy With High-Sensitivity Troponin Shows Promise Ahead of US Commercial Availability of Test L.A. McKeown April 17, 2017
News Daily News Looking Beyond Randomized Trials: Could a Wider Range of Studies Support Device Approval? Todd Neale April 05, 2017
News Daily News FDA Gives Thumbs Up to Side Branch Stent for Bifurcation Lesions Todd Neale March 06, 2017
News Daily News First High-Sensitivity Troponin Assay Finally Comes to the United States Todd Neale January 24, 2017
News Daily News TWENTE: Resolute and Xience Stents Show Comparable Outcomes up to 5 Years Michael O'Riordan January 20, 2017
News Features Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond Shelley Wood December 30, 2016
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular News and Features for 2016 Shelley Wood December 29, 2016
News Daily News La FDA Aprueba el Oclusor del FOP Amplatzer para la Prevención de ACV Recurrentes Yael L. Maxwell October 28, 2016
News Daily News FDA Approves Amplatzer PFO Occluder for Prevention of Recurrent Stroke Yael L. Maxwell October 28, 2016
News Industry News Corindus Vascular Robotics Receives FDA Clearance for Next Generation Robotic System October 27, 2016
News Daily News FDA Approves 34-mm TAVR Valve for Patients With Larger Anatomy L.A. McKeown October 27, 2016
News Daily News Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe Michael O'Riordan September 20, 2016
News Daily News FDA Expands Indications for Two Endovascular Stroke Therapies Todd Neale September 06, 2016
News Daily News TAVR as an Option for Intermediate-Risk Patients: Physicians Respond Yael L. Maxwell August 24, 2016
News Daily News Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients L.A. McKeown August 24, 2016
News Daily News FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors Michael O'Riordan August 18, 2016
News Daily News FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients Yael L. Maxwell August 18, 2016